Physician profile
Rut Dholakia
NPI 1164633913
$8,049.26
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $2,340 · 2021: $2,552 · 2022: $1,624 · 2023: $30.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $30.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $30.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $868.22 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $647.16 | 2019-2022 | |
| Abbvie INC. | $569.51 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $484.81 | 2019-2022 | |
| Biogen, INC. | $461.11 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $393.08 | 2019-2022 | |
| Amgen INC. | $383.93 | 2019-2022 | |
| Allergan, INC. | $318.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $301.22 | 2020-2022 | |
| Genzyme Corporation | $301.20 | 2019-2022 | |
| Livanova USA, INC. | $290.09 | 2019-2022 | |
| Eisai INC. | $268.20 | 2019-2022 | |
| Lilly USA, LLC | $188.60 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $186.77 | 2020-2021 | |
| Ucb, INC. | $185.82 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rut Dholakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.